[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100640850":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":26,"locations":33,"responsibleParty":51,"collaborators":25,"id":53,"slug":25,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":56,"acronym":25,"eligibilityCriteria":57,"healthyVolunteers":54,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":25,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":25,"overallStatus":35,"whyStopped":25,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Chang Gung Memorial Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Active","EXPERIMENTAL","Participants received the intervention of iTBS (The total pulse of every session is 600 pulses) over right inferior frontal gyrus for 4 weeks (5 days\u002Fweek).\n\n\\*iTBS = intermittent theta burst stimulation",[13],"Device: intermittent theta burst stimulation",{"label":15,"type":16,"description":17,"interventionNames":18},"Sham","SHAM_COMPARATOR","Participants received the sham intervention of iTBS (sham-coil) over right inferior frontal gyrus for 4 weeks (5 days\u002Fweek).",[13],[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DEVICE","intermittent theta burst stimulation","stimulatory protocol",[9,15],null,[27],{"name":28,"role":29,"phone":30,"phoneExt":31,"email":32},"Hsing-Chang Ni, Ph.D","CONTACT","88633281200","2479","alanni0918@yahoo.com.tw",[34],{"facility":5,"status":35,"city":36,"state":25,"zip":25,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"RECRUITING","Taoyuan","Taiwan","TW",{"type":40,"coordinates":41},"Point",[42,43],121.29696,24.99368,{"lat":43,"lon":42},[46,49],{"name":47,"role":29,"phone":48,"phoneExt":31,"email":32},"Hsing Chang Ni, PhD","886-3-3281200",{"name":47,"role":50,"phone":25,"phoneExt":25,"email":25},"PRINCIPAL_INVESTIGATOR",{"type":52,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100640850",false,"NCT07579494","Explore the Impacts of Theta Burst Stimulation Over the Right Inferior Frontal Gyrus in Autism Spectrum Disorder: Combination of Clinical Symptoms, Neuropsychological Function and MRI","Inclusion Criteria:\n\n* Participants aged 8 to 30 years with a clinical diagnosis of Autism Spectrum Disorder (ASD), confirmed by the ADOS-2 (Autism Diagnostic Observation Schedule, Second Edition).\n* DSM-5 severity level of ASD: level 1 or level 2\n* Participants who have been on a stable treatment regimen prior to the study, or those for whom conventional treatments have been assessed as ineffective by a physician, or those who decline conventional treatment.\n* A score of ≥ 15 on the University of California Brief Assessment of Capacity to Consent (UBACC) and demonstrated understanding of study aims and risks via the teach-back method.\n\nExclusion Criteria:\n\n* Previous or current severe neurological disorders, especially epilepsy, visual or auditory impairments\n* Previous or current severe systemic diseases such as cardiovascular disease, diabetes or hypertension\n* Previous or current severe brain injury\n* Implementation of metal materials such as a pacemaker or medication pump\n* Previous or current severe psychiatric disorders such as schizophrenia, bipolar disorder or substance abuse\n* Pregnancy\n* Presence of significant brain abnormalities, such as intracranial space-occupying lesions\n* Previous brain surgery or central nerve system infection\n* Concurrent use of medications which increased the risk of seizure attack\n* Participate in another clinical trial within one month\n* With damaged skin at the stimulated region\n* With multiple sclerosis\n* With large ischemic scars\n* Have experienced sleep disorders during brain stimulation\n* Severe alcoholism\n* Concurrent use of antiepileptic drugs\n* Uncontrollable migraines due to increased intracranial pressure\n* Unsuitable for MRI (e.g. those with claustrophobia)\n* Unsuitable for EEG\n* DSM-5 severity level of ASD: level 3\n* Current major depressive disorder\n* Suicidal ideation within one year\n* Currently taking tricyclic antidepressants (TCAs), analgesics, or any medications known to lower the seizure threshold.\n\nWithdrawal Criteria:\n\n* Seizure attack during the study period\n* Autistic symptoms worsened obviously during the study period (change of DSM-5 severity level)\n* Extreme agitation or irritability during the study period\n* Participants request\n* Clinical symptoms worsened obviously during study period\n* Start to use antiepileptic drugs during study period\n* Suicidal ideation or self-harm behaviors during study period\n* Changes in the frequency or dosage of concurrent treatments during the study period.","ALL","8 Years","30 Years",{"count":62,"type":63},60,"ESTIMATED","INTERVENTIONAL",[66],"NA","Exploring the therapeutic efficacy of Theta Burst Stimulation (TBS) over the right inferior frontal gyrus (RIFG) in autism, including changes in core symptoms, adaptive functioning, neuropsychological performance, and neurophysiological signals.",[69,70,71],"Autism Spectrum Disorder","Theta Burst Stimulation","Right Inferior Frontal Gyrus","2026-05-05",{"date":74,"type":75},"2026-05-12","ACTUAL",{"date":72,"type":75},{"date":78,"type":63},"2030-12-31",{"name":5,"class":6},1]